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In addition to their reported antitumorigenic properties, various conjugated linoleic acid (CLA) isomers have also been shown to decrease
prostanoid synthesis as a result of inhibiting the cyclooxygenase (COX) enzyme. We have previously reported that several CLA isomers
inhibited both platelet aggregation and formation of thromboxane A2 (TXA2), a proaggregatory and vasoconstrictive agent. Since the
interaction between platelets and vascular endothelial cells is essential to maintaining vascular homeostasis, we decided to investigate the
effects of various CLA isomers on the production of endothelial prostacyclin (PGI2), a potent vasodilator and inhibitor of platelet function.
Using interleukin 1-h (IL1-h)-stimulated human umbilical vein endothelial cells (HUVECs), we initially established that HUVECs of
passage #2 should be used since these cells were most responsive to thrombin-induced conversion of endogenous arachidonic acid to PGI2, as
monitored by the formation of its stable, inactive metabolite, 6-ketoPGF1a. In the first part of the study, the effects of CLA isomers in the free
fatty acid form were tested. The 10(E), 12(Z)- and 9(Z), 11(E)-CLA isomers inhibited thrombin-induced 6-ketoPGF1a formation with I50’s of
2.6 and 5.5 AM, whereas the 9(Z), 11(Z)- and 9(E), 11(E)-CLA were ineffective at concentrations up to 60 AM. The inhibitory effect of the
10(E), 12(Z)-CLAwas irreversible. Next, the effects of CLA incorporation into HUVECs on PGI2 generation was determined. An average 8-
fold stimulation of 6-ketoPGF1a formation was obtained with quiescent IL1-h-exposed HUVECs pretreated for 18 h with 25 AM 9(Z), 11(Z)-
CLA, whereas cells preincubated with the 10(E), 12(Z) isomer enhanced this eicosanoid 3-fold. Such IL1-h-treated HUVECs prelabeled with
25 AM 9(Z), 11(Z)-CLA became refractory to thrombin stimulation, as measured by 6-ketoPGF1a production, whereas a small, statistically
insignificant, inhibition was observed upon thrombin treatment of HUVECs prelabeled with the 10(E), 12(Z) isomer. Qualitative similar
results were obtained with resting or thrombin-stimulated platelets containing these esterified CLA isomers indicating that these effects occur
with cells that contain either the COX-1 or COX-2 isozymes. The results of this in vitro study indicate that the effects of CLA on cellular
prostanoid formation in endothelial cells and platelets can be either inhibitory or stimulatory, and this seems to depend not only on the
specific CLA isomer and whether or not the CLA is in the free fatty acid form or esterified into cellular lipids, but also whether cells are in the
resting or stimulated state. These findings suggest that in vivo, CLA might have multiple, complex effects on vascular homeostasis.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Conjugated linoleic acid; Endothelial prostacyclin; Cyclooxygenase enzyme
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activities including its protective effects against various
types of cancer and heart disease [1]. Recently, we reported
that various CLA isomers inhibited platelet aggregation [2].
In trying to identify some of the mechanisms through which
CLA exerts its effects, modulation of eicosanoid metabolism
was an attractive hypothesis since eicosanoids are known to
be potent modulators of certain cancers and cardiovascular
functions [3,4].
Prostanoidal eicosanoids are products of arachidonic acid
(AA) metabolism formed via the cyclooxygenase (COX)
pathway. Two such eicosanoids, prostacyclin (PGI2) anded.
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ing vascular hemostasis [4–7]. PGI2, mainly produced by
endothelial cells under physiological conditions [4,8], is
known to inhibit platelet aggregation and to act as a vaso-
dilator. In contrast, TXA2, the primary prostanoid formed by
platelets, induces platelet aggregation and acts as a vaso-
constrictor [6]. In view of their counteracting biological
effects, the PGI2/TXA2 ratio appears to be important in the
physiological regulation of vascular hemostasis. For exam-
ple, a decrease in this ratio has been related to several
pathophysiological conditions such as thrombosis and ische-
mia [4,7]. Thrombin is another important player in vascular
homeostasis via its effects on cellular kinases and phospho-
lipases and many studies have shown that thrombin can
stimulate resting human umbilical vein endothelial cells
(HUVECs) and platelets which results in enhanced forma-
tion of PGI2 and TXA2, respectively [8,9].
Since we had previously reported that certain CLA
isomers affected the formation of platelet TXA2 (as meas-
ured by its inactive metabolite TXB2 [2]) and in view of the
importance of PGI2 in maintaining normal vascular/platelet
homeostasis, studies were undertaken to examine the effects
of all pure, commercially available, CLA isomers on PGI2
production by endothelial cells. In addition, a number of
studies have reported on the effects of fatty acid incorpo-
ration on prostanoid production in endothelial cells and
platelets [10,11]. Using a similar approach, we incorporated
several CLA isomers into either endothelial cells or platelets
and investigated the effect of such esterification on the
formation of PGI2 and TXA2 by these modified cells.2. Materials and methods
Thrombin was purchased from Chronolog Corp. (Haver-
town, PA) and the 9(Z), 11(E)-CLA, 9(E), 11(E)-CLA, 9(Z),
11(Z)-CLA and 10(E), 12(Z)-CLA isomers were obtained in
>98% purity from Matreya Inc. (Pleasant Gap, PA). Pro-
duction of cellular 6-ketoPGF1a and TXB2 (the stable
hydrolysis products of PGI2 and TXA2, respectively) was
measured by enzyme immunoassay (EIA) using commercial
kits from Assay Designs Inc. (Ann Arbor, MI) and follow-
ing the manufacturer’s instructions. The cross-reactivities of
both the 6-ketoPGF1a and TXB2 antisera for other common
prostanoids were generally <0.01% range. Silica gel G 60
thin-layer chromatography (TLC) plates (Merck), common
chemicals and reagents were obtained from Fisher Scientific
and [3H]-TXB2 was purchased from Amersham Pharmacia
Biotech (Piscataway, NJ). Fatty acid-free human serum
albumin (HSA), aspirin and gelatin were purchased from
Sigma Chemical Co. (St. Louis, MO).
HUVECs (cryopreserved, obtained from pooled donors)
were purchased from Biowhittaker (Walkersville, MD). The
cells (1–4104/well in a 12-well plate) were cultured on
gelatin-coated plates in modified EGM medium supple-
mented with growth factors and a final 2% serum concen-tration as recommended by the manufacturer (Biowhittaker).
Cells between passages #2 and #4 were used and allowed to
reach confluence (6 days,f105/well). After removal of the
medium and washing the cells twice with RPMI 1640, EGM
medium containing 1% defatted fetal bovine serum (FBS)
and interleukin 1-h (IL1-h, 100 u/ml) was added and the
HUVECs were incubated overnight at 37 jC. I50 determi-
nations for the free fatty acid form of CLA were carried out
as follows: after removal of the medium, the cells were
washed twice with RPMI 1640 and then incubated in RPMI
(1 ml) containing the appropriate amount of CLA isomer or
vehicle (ethanol). After 5 min, thrombin (0.2 u/ml) was
added. Cell supernatants were collected 15 min after throm-
bin addition, acidified with 10% formic acid, neutralized
after 15 min and stored at 20 jC until 6-ketoPGF1a
analysis by EIA.
In the CLA-prelabeled HUVEC experiments, HUVECs
(passage #2) were treated with IL1-h and with or without
CLA isomers according to the method of Lagarde et al.
[11,12]. Briefly, CLA/HSA mixtures were prepared by first
evaporating (under nitrogen) solvent from ethanolic CLA
isomer stock solutions, then adding EGM buffer, pH 7.2
containing 3% HSA and incubating the mixture under a
nitrogen atmosphere for 18 h at 37 jC. Confluent
HUVECs (after washing as described above) in EGM
medium containing 1% defatted FBS and IL1-h (100 u/
ml) were incubated with EGM medium containing either
CLA-treated HSA or HSA (control) for 18 h at 37 jC.
HUVECs were then either untreated or treated with
thrombin (0.2 u/ml) for 15 min. The supernatants were
removed, processed and analyzed for 6-ketoPGF1a content
as described above.
Platelets, obtained from human donors who had not
taken any nonsteroidal antiinflammatory drugs during the
previous 2 weeks, were isolated according to our previously
reported procedure and were resuspended at a concentration
of 108/ml of Tyrode–HEPES buffer, pH 7.4 [2]. Aggrega-
tion studies, using a Chronolog model 440 VS dual aggreg-
ometer, were carried out as previously described [2]. Briefly,
control platelets (1 ml) were placed in the aggregometer and
the thrombin concentration needed to produce 40–50% of
maximum response was determined. I50’s of CLA isomers
(as the free fatty acids) were determined as previously
reported [2]. Incorporation of CLA isomers into platelets
was carried out by incubating CLA-precoated HSA- or
HSA–Tyrode–HEPES buffer preparations with platelets
for 2 h at 25 jC. After removing the HSA or CLA/HSA
media by low-speed centrifugation, the platelets were resus-
pended in Tyrode–HEPES buffer (108/ml) and placed in the
aggregometer. Platelets were preincubated for 2 min at 37
jC, then either untreated or stimulated with thrombin
(0.02–0.05 u/ml, using a concentration selected with control
platelets) for 3 min. Platelets were then extracted as pre-
viously described [2], but in the presence of 100 nCi [3H]-
TXB2 for final yield recovery determinations. TXB2 was
separated by TLC, extracted from the silicic acid and
Table 1
Influence of cell passage number on thrombin-induced 6-ketoPGF1a
formation by IL-1h pretreated HUVECs
Cell Cell treatment
passage #
+Thrombin +9(Z), 11(E)-CLA
+thrombin
6-ketoPGF1a formation
Range (pg/ml) Fold stimulation
by thrombin
(meanFS.D.)
Inhibitory
2 45–3150 (n=9) 1.6–12 (3.9F3.5) n=6 of 8
3 22–250 (n=5) 1.0–2.2 (1.6F0.43) n=1 of 4
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duplicate and final values adjusted for recovery.
In order to determine the fatty acid content of platelets
pretreated with CLA isomers, platelet lipids were extracted
using the Bligh and Dyer method [13]. Total lipids were
transmethylated using sodium methoxide and the fatty acid
methyl esters were analyzed by gas–liquid chromatography
(GLC) using a 100 m CP Sil 88 column and a temperature
program from 45 to 215 jC [14].
Results are expressed as the meanFS.D. Statistical sig-
nificance was examined by Student’s t-test, using P<0.05 as
the significance level.
4 17–210 (n=5) 1.1–2.3 (1.8F0.51) n=1 of 3
HUVECs (120,000/well) were treated for 24 h with 100 A IL-1h, followed
either by no treatment or by the addition of 0.2 u thrombin. When the effect
of CLA on 6-ketoPGF1a formation in HUVECs was tested, the IL-1h-
treated cells were first treated with either dimethylsulfoxide (vehicle) or
with varying amounts of 9(Z), 11(E)-CLA. Thrombin (0.2 u) was added
after 5 min and after an additional 15 min, the supernatant was removed and
assayed for 6-ketoPGF1a formation by EIA. n=Number of separate
experiments.3. Results
Since other reports had indicated that PGI2 formation (as
measured by its stable, inactive metabolite 6-ketoPGF1a)
was maximal after 16 h upon treatment of HUVECs with
IL1-h [15,16], these conditions were routinely used. How-
ever, in initial experiments with HUVECs of different
passage numbers, we observed that thrombin-induced 6-
ketoPGF1a production was quite variable. We then deter-
mined that a crucial parameter in analyzing 6-ketoPGF1a
formation in HUVECs was the relative amounts of 6-
ketoPGF1a produced in the presence and absence of throm-
bin. We designated this as the ‘fold stimulation by thrombin’
factor or ‘fst’ factor, i.e. the ratio of the amounts of 6-
ketoPGF1a formed in the presence and absence of thrombin.
In preliminary studies (not shown), we determined that 0.2
units of thrombin yielded optimum amounts of 6-
ketoPGF1a. In addition, HUVECs were routinely monitored
with COX inhibitors. Thus, we found that 3 AM NS-398, a
COX-2 inhibitor [17], and 200 AM aspirin inhibited
HUVEC 6-ketoPGF1a formation by 100% and 86%, respec-
tively (results not shown). The results shown in Table 1
indicate that while HUVECs of passage #2 produced 45–
3150 pg/ml of 6-ketoPGF1a, production of this metabolite
decreased substantially with cells of passages #3 and #4.
This was further confirmed when the ‘fst’ factor was
determined, decreasing from a mean ‘fst’ factor 3.9
(HUVEC passage #2) to the mean ‘fst’ factor of 1.6 and
1.8, respectively (cell passages #3 and #4). Furthermore,
when the effect of 9(Z), 11(E)-CLA on 6-ketoPGF1a for-
mation as a f(HUVEC passage number) was determined, it
was found that this CLA isomer inhibited 6-ketoPGF1a
formation in six of eight experiments with cells of passage
#2, but that cells of higher passage number were essentially
refractory to this CLA isomer. Consequently, only HUVECs
of passage #2 were used in subsequent experiments.
To determine the relative inhibitory potencies of several
CLA isomers on HUVEC PGI2 production, IL1-h-stimu-
lated HUVECs were pretreated with the CLA isomer for 5
min followed by the addition of thrombin. These CLA
isomers were chosen because they were the only ones
commercially available in >98% purity. Formation of theinactive PGI2 metabolite 6-ketoPGF1a was monitored by
EIA. The results shown in Table 2 indicate that the I50 of
10(E), 12(Z)-CLA was 2.6 AM, which was twice as potent
an inhibitor as 9(Z), 11(E)-CLA, whereas neither the 9(Z),
11(Z)- nor the 9(E), 11(E)-CLA isomers were appreciably
effective at concentrations up to 60 AM. The inhibitory
potency of the nonconjugated LAwas comparable to the 10,
12-CLA isomer. In order to determine if the inhibitory effect
of 10(E), 12(Z)-CLA was reversible, IL1-h-stimulated
HUVECs were pretreated with 10 AM of this CLA isomer
for 5 min, after which the incubation mixture was diluted
10-fold prior to the addition of thrombin. A 64% inhibition
of 6-ketoPGF1a formation was observed, which was com-
parable to the 61% inhibitory effect of 10 AM 10(E), 12(Z)-
CLA, but not the 11% decrease found with 1 AM of this
CLA isomer (Fig. 1).
Since Spector et al. [10,18] and Lagarde et al. [11,12] had
shown that endothelial cells and platelets incorporated
unsaturated fatty acids into their lipids and that such
incorporation attenuated eicosanoid formation generated
from endogenous AA, the effect of CLA incorporation on
6-ketoPGF1a production from CLA-enriched HUVECs was
examined. Two CLA isomers were used in these studies and
were chosen based on the results shown in Table 2 in which
the CLA isomers were in the free fatty acid form: i.e. one
isomer to be tested was the most effective inhibitor of
HUVEC 6-ketoPGF1a production [10(E), 12(Z)-CLA], and
the other CLA isomer [9(Z), 11(Z)-CLA] used was an
ineffective inhibitor. First, IL1-h-treated confluent HUVECs
were preenriched during an overnight incubation with either
HSA (fatty acid-free) or HSA precoated with one of these
CLA isomers. After removal of the HSA/CLA-prelabeling
medium, the cells were incubated for 15 min and 6-
ketoPGF1a formation measured. In four separate experi-
ments, control HUVECs produced and released 42–1000
Table 2
Relative inhibitory potencies (I50) of various conjugated linoleic acids on
thrombin-induced (a) 6-ketoPGF1a formation by IL-1h treated HUVECs
and (b) TXB2 production by platelets
Fatty acid I50 (AM)
6-ketoPGF1a formation TXB2 production
10(E), 12(Z)-CLA 2.6F1.5 (6)a 2.1F1.7 (3)
9(Z), 11(E)-CLA 5.5F3.1 (7)a,* nd
9(Z), 11(Z)-CLA >60 (5) >30 (4)
9(E), 11(E)-CLA >60 (5) nd
9(Z), 12(Z)-CLA 3.3F2.7 (4)b nd
(a) These experiments were carried out with HUVEC of passage #2 except
where indicated. Protocol was the same as indicated for Table 1. (b)
Platelets (108/ml) were placed in an aggregometer at 25 jC and were
pretreated with different concentrations of CLA in ethanol (or ethanol
alone) for 2 min. Thrombin (0.02 u) was added and the reaction terminated
after 3 min. Products were extracted and quantitated as described in
Materials and methods. n=Number of separate experiments and are
indicated in parentheses. Values given are meanFS.D. nd=Not determined.
a Includes one experiment with HUVEC of passage #4.
b Includes one experiment with HUVEC of passage #3.
*Statistically different from the I50 of 10(E), 12(Z)-CLA, P<0.06.
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with 25 AM 9(Z), 11(Z)-CLA, an average 8-fold increase
(range was 1.9–23-fold increase) in endogenous 6-
ketoPGF1a formation was observed, whereas 25 AM
10(E), 12(Z) isomer was not quite half as effective (range
was 1.5–7.5-fold increase, Fig. 2). Next, the effect of
thrombin on 6-ketoPGF1a formation from CLA-prelabeled
HUVECs was investigated. Thrombin stimulation of control
cells generated and released 110–2500 pg/ml of 6-
ketoPGF1a, which represented a 2.6-fold stimulation (‘fst’Fig. 1. Nonreversibility of the inhibitory effect of 10(E), 12(Z)-CLA on HUVE
described in the legend of Table 1. In the third incubation, HUVECs were pretreat
was diluted 10-fold prior to thrombin addition. The values are given as the mean p
10 AM CLA and diluted 10 AM CLA samples are statistically different from thefactor) in the formation of this metabolite relative to that
observed in the absence of thrombin. Thrombin stimulation
using HUVECs preenriched with either 10, 25 or 100 AM
10(E), 12(Z)-CLA resulted in a decrease in the ‘fst’ factor
from 2.6 (control) to 1.8, 1.9 or 2.2 (respectively) but this
decrease was not statistically significant (Table 3). HUVECs
preenriched with either 10 or 25 AM 9(Z), 11(Z)-CLA
appeared to be refractory to thrombin since the ‘fst’ factor
decreased to 1.2 (P<0.05) and 0.92 (P<0.01, respectively).
To determine whether both stimulatory and inhibitory
effects of these CLA isomers could also be observed with a
different cell type, we examined the interaction of these
CLA isomers with platelets in view of the importance of
vascular-platelet homeostasis. The effects of 10(E), 12(Z)-
CLA or 9(Z), 11(Z)-CLA, either as the free fatty acid or
esterified into platelet lipids, were tested on both platelet
aggregation and on TXA2 formation (as measured by its
stable, inactive metabolite TXB2). As shown in Table 2,
when the free fatty acid forms of these CLA isomers were
tested, only the 10, 12-CLA isomer was an effective
inhibitor of platelet TXB2 generation. When the effects of
CLA-enriched platelets on the generation and release of
TXB2 were investigated, the results were similar to those
obtained with CLA-prelabeled HUVECs. COX activity in
control platelets (either untreated or HSA-treated) was
monitored both in the absence and presence of 400 AM
aspirin which typically decreased TXB2 formation by 90–
95% (results not shown). Prelabeling platelets with HSA
precoated with 25 AM 9(Z), 11(Z)-CLA resulted in a 2.3-
fold increase in the formation and release of TXB2 but only
a 30% increase was observed with platelets enriched withC 6-ketoPGF1a formation. The HUVEC experiments were carried out as
ed at 37 jC with 10 AM CLA for 5 min, after which the incubation mixture
ercent of controlF S.D. from three separate experiments. The results for the
untreated controls, P<0.01.
Table 3
Effect of thrombin on 6-ketoPGF1a formation by IL-1h-treated HUVECs
prelabeled with either 10(E), 12(Z)-CLA or 9(Z), 11(Z)-CLA
Treatment of cells Prelabeling
concentration
of CLA isomer (AM)
6-ketoPGF1a formation,
fold stimulation by
thrombin
None – 2.6F0.42 (4)
10(E), 12(Z)-CLA 10 1.8F0.53 (4)
25 1.9F1.1 (5)
100 2.2F1.1 (5)
9(Z), 11(Z)-CLA 10 1.2F0.50 (3)*
25 0.92F0.49 (5)**
HUVECs were treated overnight at 37 jC with IL-1h and either with HSA
complexed with the indicated amount of CLA isomer or with HSA alone
according to the procedure outlined by Lagarde et al. [11,12]. Insignificant
differences in cell viabilities (as measured by LDH release) were observed
between control cells and cells pretreated with CLA. After washing, the
cells were stimulated with thrombin (0.2 u), and after 15 min, the
supernatants were removed and assayed for 6-ketoPGF1a formation by EIA.
The values are the meanFS.D. and the number of separate experiments are
indicated in parentheses.
*Results that are statistically different from control, P<0.05.
**Results that are statistically different from control, P<0.01.
Table 4
Effect of thrombin on TXB2 formation by human platelets prelabeled with
either 10(E), 12(Z)-CLA or 9(Z), 11(Z)-CLA
Treatment of platelets Prelabeling
concentration of
CLA isomer (AM)
TXB2 formation, fold
stimulation by thrombin
(meanFS.D.)
None – 3.3F1.5 (5)
10(E), 12(Z)-CLA 25 3.2F2.3 (5)
9(Z), 11(Z)-CLA 25 1.3F0.2 (5)*
Human platelets were treated for 2 h at 37 jC with either HSA complexed
with 25 AM of the indicated CLA isomer or with HSA alone according to
the procedure outlined by Lagarde et al. [11,12]. After washing, the
platelets were incubated for 2 min, stimulated with 0.2 u thrombin for an
additional 3 min. The supernatants were then removed and after TLC,
assayed for TXB2 formation by EIA. The values are the meanFS.D. and the
number of separate experiments are indicated in parentheses.
*Results that are statistically different from control, P<0.05.
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with HSA precoated with 25 AM LA, no appreciable
increase in TXB2 production was observed relative to
controls (results not shown). The data in Table 4 indicate
that thrombin-induced TXB2 formation from platelets prela-
beled with HSA and 9(Z), 11(Z)-CLA was reduced as theirFig. 2. CLA-prelabeling of HUVECs and platelets increased generation and releas
for 18 h at 37 jC with IL-1h and either with HSA complexed with 25 AM of the in
by Lagarde et al. [11,12]. Insignificant differences in cell viabilities (as measured
with CLA. After washing, the cells were incubated for 15 min, the supernatants wer
were treated for 2 h at 37 jC with either HSA complexed with 25 AM of the in
maintained at room temperature for 5 min. The supernatants were then removed
meanFSD and are obtained from four (HUVECs or platelets) separate experimen‘fst’ factor was significantly lower than that of control
platelets (1.3 vs. 3.3). Prelabeling platelets with HSA and
10(E), 12(Z)-CLA did not have any appreciable effect on the
‘fst’ factor. No substantial differences were observed in
thrombin-induced aggregation between platelets incubated
only with HSA and platelets enriched with either the 9, 11-
or 10, 12-CLA isomer (results not shown).
To confirm that the CLA isomers were indeed incorpo-
rated into cells, platelets were first pretreated with either
HSA (control), 25 AM 9(Z), 11(Z)-CLA/HSA or 25 AM
10(E), 12(Z)-CLA/HSA, followed by extraction of platelete of 6-ketoPGF1a and thromboxane B2, respectively. HUVECs were treated
dicated CLA isomer or with HSA alone according to the procedure outlined
by LDH release) were observed between control cells and cells pretreated
e removed and assayed for 6-ketoPGF1a formation by EIA. Human platelets
dicated CLA isomer or with HSA alone. After washing, the platelets were
and after TLC, assayed for TXB2 formation by EIA. The values are the
ts.
Table 5
CLA incorporation into total platelet lipids
Pretreatment CLA (%) AA (%)
9(Z),
11(Z)-
10(E),
12(Z)-
9(Z),
11(E)
HSA (control) 0.03 0.03 0.14 22.91
+25 AM 9(Z), 11(Z)-CLA 0.23 0.03 0.12 22.73
+25 AM 10(E), 12(Z)-CLA 0.03 0.66 0.13 22.16
Human platelets were treated for 2 h at 37j with either HSA complexed
with 25 AM of the indicated CLA isomer or with HSA alone. After
washing, the platelets from six donors (1–3109/donor) were pooled,
extracted by the Bligh and Dyer method [13] and transmethylated using
sodium methoxide. Fatty acid methyl esters were analyzed by GLC as
described in Materials and methods.
A.P. Torres-Duarte, J.Y. Vanderhoek / Biochimica et Biophysica Acta 1640 (2003) 69–7674lipids. After transmethylation, the fatty acid methyl esters
were analyzed by GLC. As shown in Table 5, the amount of
9(Z), 11(Z)-CLA incorporated (of the total fatty acid con-
tent) increased from 0.03% (control) to 0.23%, whereas the
amount of 10(E), 12(Z)-CLA incorporated increased from
0.03% (control) to 0.66%. No appreciable differences were
observed in either the 9(Z), 11(E)-CLA isomer (typically the
major CLA isomer present in human tissues) or AA content
of the platelet lipids.4. Discussion
In the present study, we first analyzed PGI2 generation (as
measured by its stable hydrolysis product 6-ketoPGF1a) by
IL1-h-treated HUVECs that were stimulated by thrombin.
Under these conditions, PGI2 is the primary product formed
from the COX-2 isozyme pathway [15]. The ability of
thrombin to stimulate 6-ketoPGF1a production in IL1-h-
treated HUVECs appeared to be dependent on the HUVEC
passage number used. Thrombin potentiated 6-ketoPGF1a
formation in passage #2 cells about 4-fold compared to less
than 2-fold increases with cells of passage #3 or greater
(Table 1). Consequently, cells of passage #2 were routinely
used. Several studies have appeared which report similar
findings of reduced PGI2 production with increased HUVEC
passage number though different conditions were used in
these experiments [19,20]. Whether this phenomenon is due
to cell age-related downregulation of receptors, changes in
the COX isozymes or other events remains to be established.
When the effects of various CLA isomers were tested,
two isomers, the 10(E), 12(Z)- and the 9(Z), 11(E)-CLA
inhibited 6-ketoPGF1a formation by thrombin-stimulated
HUVECs with I50’s of 2.6 and 5.5 AM, respectively,
whereas the 9(Z), 11(Z)- and 9(E), 11(E)-CLA were inef-
fective at concentrations up to 60 AM (Table 2). Comparing
these values to the reported I50’s of CLA isomers on COX-
catalyzed production of eicosanoids, it appears that the
inhibitory CLA isomers were much more effective on
HUVECs which contain the COX-2 system than on cells
(e.g. platelets) containing COX-1. We have previously
reported that both the 10(E), 12(Z)- and 9(Z), 11(E)- isomersof CLA inhibited platelet TXB2 with I50’s of 13–16 AM [2].
Bulgarella et al. [22] reported that three of these CLA
isomers had I50’s of about 20 AM on the ram seminal vesicle
COX-1, with the 9(Z), 11(Z) isomer the least potent (I50
about 100 AM). These differences in I50’s could be due to
different sensitivities of the COX isozymes to CLA isomers,
the use of diverse cellular sources of these enzymes and/or
experimental conditions or inherent dissimilar mechanisms
of eicosanoid production. Similar explanations could be
advanced to explain the lack of reversibility of the inhibitory
effect of 10(E), 12(Z)-CLA (Fig. 1) which contrasts with
that observed with the 9(Z), 11(E)-CLA isomer on platelet
TXB2 formation [2].
In contrast to the above described effects of CLA isomers
in the free fatty acid form, studies were conducted to explore
the possibility that incorporation of CLA into HUVEC
lipids also might influence 6-ketoPGF1a formation. Cells
were prelabeled with either the 10(E), 12(Z)- or 9(Z), 11(Z)-
CLA. These two isomers were chosen because in the free
fatty acid form, they represented the most and least effective
inhibitors, respectively, of HUVEC PGI2 formation. Unex-
pectedly, an 8-fold increase in 6-ketoPGF1a production was
observed in quiescent, IL1-h-treated cells that had been
prelabeled with the 9(Z), 11(Z) isomer, whereas less than
half that increase was obtained with the 10(E), 12(Z) isomer
(Fig. 2). A number of groups have reported that incorpo-
ration of unsaturated fatty acids, such as linoleic acid,
eicosapentaenoic and docosahexaenoic acid, into HUVECs
and platelets decreased cellular eicosanoid formation from
endogenous AA (e.g. Refs. [10–12,18]). In contrast to these
results, a 2- to 3-fold increase in 6-ketoPGF1a formation
was observed during a PUFA enrichment process of
HUVECs (untreated with any inducer of COX-2) with either
22:6 or 20:5, but the authors of this study did not report on
the ability of these cells to stimulate 6-ketoPGF1a produc-
tion after removal of the PUFA-containing medium [21].
Most recently, Urquhart et al. [23] tested the effects of the
incorporation of 9(Z), 11(E)- and 10(E), 12(Z)-CLA isomers
on COX-1 activity in human saphenous vein endothelial
cells. These authors reported that 50 AM of either CLA
isomer inhibited PGF2a formation in resting cells although
major differences in their protocol and experimental con-
ditions can readily explain the different results obtained in
their work and ours. The results of our study also indicate
that the ability of certain CLA isomers to stimulate endog-
enous prostanoid formation was not limited to HUVECs
since enhanced TXB2 production was also observed in
nonstimulated platelets pretreated with 9(Z), 11(Z)-CLA
(Fig. 2). Furthermore, structural differences between CLA
isomers can account for the different stimulatory potencies.
It is possible that the presence of a conjugated diene
functionality is important (but not sufficient) as no stimula-
tory effect on platelet TXB2 production was observed with
platelets enriched with a nonconjugated PUFA, i.e. LA. The
much larger (8-fold) increase in prostanoid formation
observed with prelabeled HUVECs compared to that
A.P. Torres-Duarte, J.Y. Vanderhoek / Biochimica et Biophysica Acta 1640 (2003) 69–76 75obtained with prelabeled platelets (2-fold) might be due to
either cell differences or to the different CLA pretreatment
times used as the HUVECs were pretreated with CLA for
18 h compared to a 2 h pretreatment of platelets.
Short-term (i.e. minutes) exposure of cells to thrombin is
known to stimulate cellular phospholipases to release
endogenous AA which results in increased formation of 6-
ketoPGF1a [8]. Thrombin appeared to have similar stim-
ulatory effects on HUVEC 6-ketoPGF1a formation due to
either COX-1 or COX-2 (data not shown). When the effects
of thrombin on CLA-enriched HUVECs prestimulated with
IL1-h were studied, a statistically significant decrease in 6-
ketoPGF1a production was observed (relative to nonen-
riched cells) when the cells were prelabeled with the 9(Z),
11(Z)-CLA isomer, whereas a small (not significant statisti-
cally) decrease was obtained with cells enriched with 10(E),
12(Z) isomer (Table 3). Similar results have been reported
by Bordet et al. [11] who used HUVECs that had been
preenriched with PUFAs such as 18:2 (n-6) or 18:3 (n-3)
though these studies did not involve COX-2 induction. It is
possible that the inability of thrombin to stimulate 6-
ketoPGF1a formation in HUVECs prelabeled with the
9(Z), 11(Z) isomer might be due to the fact that incorpo-
ration of this CLA isomer into cellular lipids resulted in a
changed microenvironment of endogenous esterified AA so
that lipids containing AA became less accessible to the
phospholipases activated by thrombin. Alternatively, the
COX-2 in resting HUVECs prelabeled with the 10(E),
12(Z)-CLA was in a less active state compared to HUVECs
prelabeled with the 9(Z), 11(Z) isomer so that thrombin
could still have a stimulatory effect on the former cells.
Dairy and meat products are the main dietary sources of
CLA and the major CLA isomer present is 9(Z), 11(E)-CLA
[24]. This isomer has been reported to be a potent anti-
carcinogenic agent [25] and inhibited the growth of human
mammary cancer cells [26]. A number of studies indicate
that other CLA isomers, though minor components of the
naturally occurring CLA isomeric mix, also exhibit bio-
logical properties, e.g. 10(E), 12(Z)-CLA reduced leptin
secretion [27] and inhibited the growth of preadipocytes
[27] and the 9(Z), 11(Z)-CLA isomer was a potent inducer
of gene expression in COS-1 cells [28]. Our findings
confirm potent biological effects of these ‘minor’ CLA
isomers on HUVECs and platelets, two cell types essential
in vascular homeostasis. Our observation that 9(Z), 11(Z)-
CLA incorporated into HUVEC lipids stimulated PGI2
formation but had no effect as the free acid suggest that
the use of this specific CLA isomer in the diet might have
beneficial antithrombogenic effects. Furthermore, the
greater stimulation observed in HUVEC PGI2 production
than platelet TXA2 formation seems to suggest that this
CLA isomer increases the PGI2/TXA2 balance. As separate
cell populations were used in these studies, more work
needs to be done using mixed HUVEC-platelet populations
in order to delineate the optimum conditions under which
9(Z), 11(Z)-CLA could play an antithrombotic role.In summary, our in vitro findings indicate that CLA
isomers appear to have multiple and complex effects on
COX-catalyzed prostanoid formation in endothelial cells
and platelets. These effects depend on the specific CLA
isomer, whether the isomer is in the free fatty acid form or
esterified into cellular lipids and whether the target cell is in
a quiescent or active state. Since it is quite likely that the in
vivo CLA effects are even more complex, our results
coupled with the increased use of CLA isomer mixtures as
dietary supplements point up the need for new dietary
studies to explore the use of specific CLA isomers as
antithrombogenic agents.Acknowledgements
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